Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab ± cisplatin with radiotherapy vs cetuximab ± cisplatin with radiotherapy in locally advanced SCCHN
jRCT2080223754Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Ono Pharmaceutical. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080223754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223754.